36 research outputs found
Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men
CONTEXT: Strontium ranelate reduces vertebral and nonvertebral fracture risk in postmenopausal osteoporosis.
OBJECTIVE: The objective of this study was to determine the efficacy and safety of strontium ranelate in osteoporosis in men over 2 years (main analysis after 1 year).
DESIGN: This was an international, unbalanced (2:1), double-blind, randomized placebo-controlled trial (MALEO [MALE Osteoporosis]).
SETTING: This international study included 54 centers in 14 countries.
PARTICIPANTS: PARTICIPANTS were 261 white men with primary osteoporosis.
INTERVENTION: Strontium ranelate at 2 g/d (n = 174) or placebo (n = 87) was administered.
MAIN OUTCOME MEASURES: Lumbar spine (L2-L4), femoral neck, and total hip bone mineral density (BMD), biochemical bone markers, and safety were measured.
RESULTS: Baseline characteristics were similar in both groups in the whole population (age, 72.9 ± 6.0 years; lumbar spine BMD T-score, -2.7 ± 1.0; femoral neck BMD T-score, -2.3 ± 0.7). Men who received strontium ranelate over 2 years had greater increases in lumbar spine BMD than those who received placebo (relative change from baseline to end, 9.7% ± 7.5% vs 2.0% ± 5.5%; between-group difference estimate (SE), 7.7% (0.9%); 95% confidence interval, 5.9%-9.5%; P < .001). There were also significant between-group differences in relative changes in femoral neck BMD (P < .001) and total hip BMD (P < .001). At the end of treatment, mean levels of serum cross-linked telopeptides of type I collagen, a marker of bone resorption, were increased in both the strontium ranelate group (10.7% ± 58.0%; P = .022) and the placebo group (34.9% ± 65.8%; P < .001). The corresponding mean changes of bone alkaline phosphatase, a marker of bone formation, were 6.4% ± 28.5% (P = .005) and 1.9% ± 25.4% (P = .505), respectively. After 2 years, the blood strontium level (129 ± 66 μmol/L) was similar to that in trials of postmenopausal osteoporosis. Strontium ranelate was generally well tolerated.
CONCLUSIONS: The effects of strontium ranelate on BMD in osteoporotic men were similar to those in postmenopausal osteoporotic women, supporting its use in the treatment of osteoporosis in men
Management of osteoporosis in the elderly
Background: Osteoporosis is predominantly a condition of the elderly, and the median age for hip fracture in women is approximately 83 years. Osteoporotic fracture risk is multifactorial, and often involves the balance between bone strength and propensity for falling. Objective: To present an overview of the available evidence, located primarily by Medline searches up to April, 2009, for the different management strategies aimed at reducing the risk of falls and osteoporotic fractures in the elderly. Results: Frailty is an independent predictor of falls, hip fractures, hospitalisation, disability and death in the elderly that is receiving increasing attention. Non-pharmacological strategies to reduce fall risk can prevent osteoporotic fractures. Exercise programmes, especially those involving high doses of exercise and incorporating balance training, have been shown to be effective. Many older people, especially the very elderly and those living in care institutions, have vitamin D inadequacy. In appropriate patients and given in sufficient doses, vitamin D and calcium supplementation is effective in reducing both falls and osteoporotic fractures, including hip fractures. Specific anti-osteoporosis drugs are underused, even in those most at risk of osteoporotic fracture. The evidence base for the efficacy of most such drugs in the elderly is incomplete, particularly with regard to nonvertebral and hip fractures. The evidence base is perhaps most complete for the relatively recently introduced drug, strontium ranelate. Non-adherence to treatment is a substantial problem, and may be exacerbated by the requirements for safe oral administration of bisphosphonates. Conclusion: Evidence-based strategies are available for reducing osteoporotic fracture risk in the elderly, and include exercise training, vitamin D and calcium supplementation, and use of evidence-based anti-osteoporotic drugs. A positive and determined approach to optimising the use of such strategies could reduce the burden of osteoporotic fractures in this highrisk group. © 2009 Informa UK Ltd. All rights reserved
The position of Strontium ranelate in today's management of osteoporosis
Osteoporosis accounts for about 3 % of total European
health-care spending. The low proportion of costs for the
pharmacological prevention of osteoporotic fracture means
that it is highly cost saving, especially in patient with severe
osteoporosis or patients who cannot take certain osteoporosis
medications due to issues of contraindications or tolerability.
Following recent regulatory changes, strontium ranelate is
now indicated in patients with severe osteoporosis for whom
treatment with other osteoporosis treatments is not possible,
and without contraindications including uncontrolled hypertension,
established, current or past history of ischaemic heart
disease, peripheral arterial disease, and/or cerebrovascular disease.
We review here today’s evidence for the safety and efficacy
of strontium ranelate. The efficacy of strontium ranelate
in patients complying with the new prescribing information
(i.e. severe osteoporosis without contraindications) has been
explored in a multivariate analysis of clinical trial data, which
concluded that the antifracture efficacy of strontiumranelate is
maintained in patients with severe osteoporosis without contraindications
and also demonstrated how the new target population
mitigates risk. Strontium ranelate is therefore an important
alternative in today’s management of osteoporosis,
with a positive benefit-risk balance, provided that the revised
indication and contraindications are followed and cardiovascular
risk is monitored. The bone community should be
reassured that there remain viable alternatives in patients in
whom treatment with other agents is not possible and protection
against the debilitating effects of fracture is still feasible in
patients with severe osteoporosis